Sotera Health Croissance future
Future contrôle des critères 4/6
Sotera Health devrait augmenter ses bénéfices et son chiffre d'affaires de 29% et de 5.7% par an respectivement. Le BPA devrait croître de de 28.2% par an. Le rendement des capitaux propres devrait être 25.7% dans 3 ans.
Informations clés
29.0%
Taux de croissance des bénéfices
28.22%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 16.9% |
| Taux de croissance des recettes | 5.7% |
| Rendement futur des capitaux propres | 25.75% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 08 Jul 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.Mise à jour du récit • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Article d’analyse • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...Mise à jour du récit • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.Mise à jour du récit • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).Mise à jour du récit • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).Mise à jour du récit • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).Mise à jour du récit • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.Mise à jour du récit • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.Seeking Alpha • Feb 20
Sotera Health: A Predictable And Growing Business
Summary Sotera Health's stock was volatile in 2025 but ultimately finished strong. The core business remains a stable franchise that has consistently grown sales and operating profits with zero down years in the last 20 years. 2025 marked an inflection year, with the core Sterigenics segment posting 10% revenue growth, up from ~4-7% in the previous two years. Read the full article on Seeking AlphaMise à jour du récit • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).Mise à jour du récit • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
Nouveau récit • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).Article d’analyse • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...Mise à jour du récit • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.Mise à jour du récit • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).Mise à jour du récit • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.Article d’analyse • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...Article d’analyse • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...Mise à jour du récit • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.Mise à jour du récit • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.Mise à jour du récit • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.Article d’analyse • Aug 13
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
Sotera Health Company ( NASDAQ:SHC ) shareholders would be excited to see that the share price has had a great month...Mise à jour du récit • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.Article d’analyse • Jul 17
These 4 Measures Indicate That Sotera Health (NASDAQ:SHC) Is Using Debt Extensively
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nouveau récit • Sep 02
Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth
Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 1,395 | 290 | N/A | 467 | 5 |
| 12/31/2027 | 1,314 | 245 | 222 | 417 | 9 |
| 12/31/2026 | 1,241 | 201 | 120 | 326 | 9 |
| 3/31/2026 | 1,189 | 118 | 97 | 261 | N/A |
| 12/31/2025 | 1,164 | 78 | 149 | 287 | N/A |
| 9/30/2025 | 1,150 | 55 | 87 | 240 | N/A |
| 6/30/2025 | 1,125 | 24 | 113 | 266 | N/A |
| 3/31/2025 | 1,107 | 25 | 106 | 270 | N/A |
| 12/31/2024 | 1,100 | 44 | 45 | 224 | N/A |
| 9/30/2024 | 1,120 | 70 | 104 | 282 | N/A |
| 6/30/2024 | 1,098 | 40 | 32 | 226 | N/A |
| 3/31/2024 | 1,077 | 55 | -377 | -172 | N/A |
| 12/31/2023 | 1,049 | 51 | -363 | -148 | N/A |
| 9/30/2023 | 991 | -306 | -381 | -159 | N/A |
| 6/30/2023 | 976 | -268 | -342 | -133 | N/A |
| 3/31/2023 | 988 | -261 | 70 | 262 | N/A |
| 12/31/2022 | 1,004 | -234 | 96 | 278 | N/A |
| 9/30/2022 | 993 | 121 | 90 | 242 | N/A |
| 6/30/2022 | 971 | 123 | 127 | 256 | N/A |
| 3/31/2022 | 956 | 135 | 159 | 275 | N/A |
| 12/31/2021 | 931 | 115 | 179 | 282 | N/A |
| 9/30/2021 | 907 | 36 | 156 | 237 | N/A |
| 6/30/2021 | 881 | 9 | 127 | 202 | N/A |
| 3/31/2021 | 842 | -26 | 110 | 171 | N/A |
| 12/31/2020 | 818 | -39 | 67 | 121 | N/A |
| 9/30/2020 | 795 | -23 | 55 | 109 | N/A |
| 6/30/2020 | 790 | -28 | 68 | 124 | N/A |
| 3/31/2020 | 772 | -29 | 58 | 116 | N/A |
| 12/31/2019 | 778 | -21 | N/A | 149 | N/A |
| 12/31/2018 | 746 | -6 | N/A | 120 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SHC ( 29% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de SHC ( 29% par an) devraient croître plus rapidement que le marché US ( 18.2% par an).
Croissance élevée des bénéfices: Les bénéfices de SHC devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de SHC ( 5.7% par an) devrait croître plus lentement que le marché de US ( 13% par an).
Croissance élevée des revenus: Le chiffre d'affaires de SHC ( 5.7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de SHC devrait être élevé dans 3 ans ( 25.7 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/13 18:02 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Sotera Health Company est couverte par 12 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |